Parkinson's DiseaseNCT02915848
Long-term Stability of LFP Recorded From the STN and the Effects of DBS
An observational study of Parkinson's Disease, run by University Health Network, Toronto at 1 site in Canada.
Trial summary
Movement disorders such as Parkinson Disease, dystonia, and tremor are related to abnormalities of part of the brain known as the basal ganglia. Recently, it has been suggested that the basal ganglia works by oscillations (group of neurons cycle between activation/deactivation when stimulated) of electrical signals. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Parkinson's Disease
- What is being tested?
- PC+S group
- Type of treatment
- Medical device
- How many people
- 10 participants
- Where
- 1 siteCanada
- Study dates
- 9 Sep 2016to 26 Apr 2021
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Parkinson's disease patients scheduled to undergo STN DBS surgery
Who may be able to join
- PD Patients scheduled to undergo bilateral STN DBS surgery.
- No previous brain surgery or other neurological disorders
- No unstable medical conditions
- Able to provide informed consent and comply with study protocol
Who cannot join
- 1. previous brain surgery or other neurological disorders unstable medical conditions
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Long-term Stability of Local Field Potentials Recorded From the Subthalamic Nucleus and the Effects of Deep Brain Stimulation
Movement disorders such as Parkinson Disease, dystonia, and tremor are related to abnormalities of part of the brain known as the basal ganglia. Recently, it has been suggested that the basal ganglia works by oscillations (group of neurons cycle between activation/deactivation when stimulated) of electrical signals. A treatment that involves insertion of electrodes in the subthalamic nucleus (STN) for electrical stimulation, known as deep brain stimulation (DBS), is an established treatment for advanced Parkinson's disease. However its mechanism of action is still not completely understood. Currently, DBS utilizes an "open loop" system whereby the stimulation settings are manually adjusted depending on the patients' clinical response.
- Determine whether the local field potential (LFP) recorded from the STN is stable over a 1.5 year period.
- Address whether STN LFP is a suitable control signal, and how it should be used to change DBS parameters
Read the detailed description
Study Design and Methods
Ten Parkinson's disease (PD) patients who are scheduled for bilateral STN DBS will be recruited. DBS surgery will be performed at the Toronto Western Hospital as per standard clinical care. The studies will be performed at two sites: Toronto Western Hospital and London Mobility Laboratory at Western University. Recording of STN LFP using externalized DBS leads, the effects DBS at different frequencies on PD motor symptoms will be studied at the Toronto Western Hospital. Gait studies with full body kinematic measurements, recording of LFP and effects of different stimulation frequencies will be studied at the London Mobility Laboratory (LML) at Western University.
An outline of the study timeline is provided in Table (2, 3 and 4). Standardized tasks performed are provided in Table 5.Ten PD patients with bilateral DBS in STN will be studied for six visits to each site (TWH and LML). There will also be a presurgical baseline visit to LML. Patients will first be studied 1-3 days after DBS electrode implantation and before the implantation of the pulse generator. Local field potential (LFP) will be recorded from bilateral STN DBS electrodes using externalized leads. Following internalization of the DBS leads and insertion of the pulse generator (Activa PC+S, Medtronic), patients will be studied within 7 days for a second visit. DBS programming will be performed as per usual clinical practice. Patients will then be studied at 1, 2, 6, 12 and 18 months postoperatively.
Visits at the Toronto Western Hospital (TWH)
Visit 1 (TWH V1) This visit will obtain "acute" LFP recording for comparison to chronic recordings. Patients will be studied 1-3 days after electrode insertion when the leads are externalized. This is a two day visit, with one day in the off medication state (overnight withdrawal) and one day in the on medication state in random order. For the on medication state, 125% of the levodopa equivalent of the first morning preoperative dose will be administered to increase the chance of recording levodopa-induced dyskinesia.
Stage 1: LFP will be recorded from bilateral STN DBS electrodes together with scalp EEG. Fig. 3 shows a schematic representation of the recording setup. Surface EMG and accelerometery will be used to measure the tremor frequencies and levodopa-induced dyskinesias. mUPDRS and the Rush dyskinesia rating scale (for on medication recordings) assessments will be performed. Recordings will be made at rest and while the patients perform self-paced wrist extension movements. The most prominent LFP frequencies in the θ, β and γ band oscillations at rest and during voluntary movements in both on and off medication states (individualized frequencies) as well as the electrode contact that shows the most prominent LFP oscillations will be determined for each patient. This recording will take about one hour. The data analysis will take one hour during which the patient will have a break.
Stage 2: This will involve stimulation. The DBS leads will be connected to an external stimulator and a "filter DBS" device to record LFP during DBS. Four DBS conditions will be studied in random order:
- high frequency (185 Hz), 2) the individualized γ frequency that show maximum peak at rest (γ rest, determined from stage 1), 3) the individualized γ frequency that show maximum increase with voluntary movements (γ movement, determined from stage 1), and 4) no stimulation. The contact will be selected based on location within the STN from postoperative MRI using methods published by our group and maximum changes in the θ and β bands with voluntary movements (Stage 1). The selected DBS contact will be the cathode (-ve) and anode (+ve) will be a surface electrode placed on the chest wall (similar to contact -ve, case +ve commonly used in therapeutic DBS). Pulse width will be set at100 μs and the current will be the highest (maximum 5 mA) without inducing adverse effect. LFP will be recorded from the electrode contacts adjacent to the one used for DBS using a bipolar montage to allow for maximum cancellation of stimulus artifacts. For example, if contact 2 is used for DBS, LFP will be recorded from contacts 1 and 3. For each condition, 15 min of DBS while resting will be followed by mUPDRS assessment while DBS is maintained. Patients will be video recorded to allow subsequent video scoring of mUPDRS and the Rush dyskinesia rating scale by blinded raters. DBS for the right and left STN will be studied in random order, with one side in the morning and one side in the afternoon. Investigators have performed more complex stimulation protocols in PD patients with STN DBS.
The second day of study will occur the next day. The procedure will be the same as Day 1 except that the medication status (on or off medication) will alternate with Day 1 in random order.
Visit 2 (TWH-V2) The purpose of this visit is to obtain early LFP recording from the Activa PC+S device before DBS programming begins. This visit will be conducted within 4 weeks of internalization of the DBS leads and insertion of the pulse generator (Activa PC+S), but before the pulse generator is turned on for programming. The visit will be conducted over two days, one day in the off medication state (overnight withdrawal) and one day in the on medication state in random order as in Visit 1. The procedure is identical for Visit 1 with recording of LFP at rest and during a self-paced wrist extension task, followed by testing of 4 different stimulation conditions. However, LFP will be recorded from the Activa PC+S device using the real-time uplink mode to provide continuous recording rather than from externalized leads. Since the device can only record LFP from one pair of contacts from each electrode (right and left) at a time, for recordings in the resting state to examine the difference between on and off medications, investigators will use the "montage sweep" mode that will record alternately from all six possible combinations of bipolar contacts (0-1, 1-2, 2-3, 0-2, 0-3, 1-3) for each electrode. For the wrist extension movements, we will record from the bipolar contact pair that produced the greatest change in γ oscillations with dopaminergic medications and voluntary movements based on the results of Visit 1. In addition, we will record from the adjacent contact pair. For example, if contact 1-2 was found to produce the maximum γ peak, contacts 1-2 as well as contacts 0-1 and 2-3 will be studied. Each pair of electrode contacts will be studied in separate runs. Following the LFP recording (stage 1), the individual γ frequency peaks will be established. Stage 2 will study the effects of DBS at high frequency, γ rest, γ movement and no stimulation assessed in random order with recording of STN LFP during stimulation as in Visit 1. The same contact used for DBS in Visit 1 will be used with monopolar montage (contact -ve, case +ve). LFP with be recorded from the adjacent contacts with bipolar montage as described in Visit 1 but the implanted Activa PC+S device will be used for LFP recording
Visits 3- 6 (TWH-V3, V4, V5 and V6) After Visit 2, DBS programming will be performed as per usual clinical practice and takes about 2-4 weeks to complete. Patients will then be studied at 2, 6, 12, and 18 months after surgery. The assessment procedure will be identical to that for Visit 2 except that the "high" frequency stimulation setting will be the setting normally used by the patient for clinical benefit (130-185 Hz) instead of 185 Hz.
Visits at London Mobility Laboratory (Western University) Visit 1 will occur before surgery to obtain baseline gait and kinematic measurements data in the on and off medication states. For visits 2, 3 and 7, the TWH visits will occur 1-5 days before the London Mobility Laboratory visits. The γ frequency stimulation to be used in the London Mobility Laboratory visits will be the "γ movement" frequency determined from the corresponding TWH visit.
- Conditions
- Parkinson's Disease
- Being tested
- PC+S group
- Keywords
- deep brain stimulation, local field potential, kinematic analysis
- Medical subject headings
- Parkinson Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PC+S groupDevice
PC+S group: participants in the study will also receive a specific stimulation device (Activa PC+S, Medtronic) that is capable of recording the local field potentials (LFP). Approximately 10 participants are expected to take part in this study at UHN.
| Study group | Role | What they receive |
|---|---|---|
| PC+S group | PC+S group gets Medtronic, Activa PC+S DBS device, Receives: Device: PC+S group |
What is being measured
The primary outcome is the main question the study is designed to answer.
Clinical measure of Parkinsonism: Unified Parkinson's disease rating scale
Clinical scales of Parkinson's disease will be measured using Unified Parkinson's disease rating scale at different time points (visits) of the study
Measured: Through study completion, an average of 1.5 year
Secondary outcomes (2)
Kinetic measures of walking
Gait parameters including temporal spatial measures (e.g., stride length, speed), center of pressure and estimated center of mass as well as the temporal segmentation of task components
Measured: Through study completion, an average of 1.5 year
Electrophysiologic measures of brain activity
Power spectral analysis of local field potential and coherence analysis between these local field potential and electromyography \& electroencephalography measures
Measured: Through study completion, an average of 1.5 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Sep 2016 (estimated)
- Study start9 Sep 2016
- Primary completion26 Apr 2021
- Study completion26 Apr 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Parkinson's DiseaseStudies of the same condition, open and under way.
- More trials run by University Health Network, TorontoThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 10 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Health Network, Toronto
- Sponsor type
- University, hospital or other
- Collaborators
- Medtronic
- Responsible party
- Principal investigator, Robert Chen, University Health Network, Toronto
- Investigators
- Robert Chen, FRCPC, Principal investigator, University Health Network, Toronto
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02915848
- Sponsor's protocol ID
- UHNToronto: 12-5452-B
- Status last verified
- Apr 2021
- First submitted
- 13 Sep 2016
- Last updated
- 27 Apr 2021
- Results posted
- No
- Data monitoring committee
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Apr 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Long-term Stability of Local Field Potentials Recorded From the Subthalamic Nucleus and the Effects of Deep Brain Stimulation
- ClinicalTrials.gov ID
- NCT02915848
- Acronym / sponsor ID
- UHNToronto: 12-5452-B
- Conditions
- Parkinson's Disease
- Keywords
- deep brain stimulation, local field potential, kinematic analysis
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 10 participants (actual)
- Lead sponsor
- University Health Network, TorontoUniversity, hospital or other
- Collaborators
- Medtronic
- Study start
- 9 Sep 2016 (actual)
- Primary completion
- 26 Apr 2021 (actual)
- Study completion
- 26 Apr 2021 (actual)
- First posted
- 27 Sep 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Movement disorders such as Parkinson Disease, dystonia, and tremor are related to abnormalities of part of the brain known as the basal ganglia. Recently, it has been suggested that the basal ganglia works by oscillations (group of neurons cycle between activation/deactivation when stimulated) of electrical signals. A treatment that involves insertion of electrodes in the subthalamic nucleus (STN) for electrical stimulation, known as deep brain stimulation (DBS), is an established treatment for advanced Parkinson's disease. However its mechanism of action is still not completely understood. Currently, DBS utilizes an "open loop" system whereby the stimulation settings are manually adjusted depending on the patients' clinical response.
- Determine whether the local field potential (LFP) recorded from the STN is stable over a 1.5 year period.
- Address whether STN LFP is a suitable control signal, and how it should be used to change DBS parameters
Detailed description
Study Design and Methods
Ten Parkinson's disease (PD) patients who are scheduled for bilateral STN DBS will be recruited. DBS surgery will be performed at the Toronto Western Hospital as per standard clinical care. The studies will be performed at two sites: Toronto Western Hospital and London Mobility Laboratory at Western University. Recording of STN LFP using externalized DBS leads, the effects DBS at different frequencies on PD motor symptoms will be studied at the Toronto Western Hospital. Gait studies with full body kinematic measurements, recording of LFP and effects of different stimulation frequencies will be studied at the London Mobility Laboratory (LML) at Western University.
An outline of the study timeline is provided in Table (2, 3 and 4). Standardized tasks performed are provided in Table 5.Ten PD patients with bilateral DBS in STN will be studied for six visits to each site (TWH and LML). There will also be a presurgical baseline visit to LML. Patients will first be studied 1-3 days after DBS electrode implantation and before the implantation of the pulse generator. Local field potential (LFP) will be recorded from bilateral STN DBS electrodes using externalized leads. Following internalization of the DBS leads and insertion of the pulse generator (Activa PC+S, Medtronic), patients will be studied within 7 days for a second visit. DBS programming will be performed as per usual clinical practice. Patients will then be studied at 1, 2, 6, 12 and 18 months postoperatively.
Visits at the Toronto Western Hospital (TWH)
Visit 1 (TWH V1) This visit will obtain "acute" LFP recording for comparison to chronic recordings. Patients will be studied 1-3 days after electrode insertion when the leads are externalized. This is a two day visit, with one day in the off medication state (overnight withdrawal) and one day in the on medication state in random order. For the on medication state, 125% of the levodopa equivalent of the first morning preoperative dose will be administered to increase the chance of recording levodopa-induced dyskinesia.
Stage 1: LFP will be recorded from bilateral STN DBS electrodes together with scalp EEG. Fig. 3 shows a schematic representation of the recording setup. Surface EMG and accelerometery will be used to measure the tremor frequencies and levodopa-induced dyskinesias. mUPDRS and the Rush dyskinesia rating scale (for on medication recordings) assessments will be performed. Recordings will be made at rest and while the patients perform self-paced wrist extension movements. The most prominent LFP frequencies in the θ, β and γ band oscillations at rest and during voluntary movements in both on and off medication states (individualized frequencies) as well as the electrode contact that shows the most prominent LFP oscillations will be determined for each patient. This recording will take about one hour. The data analysis will take one hour during which the patient will have a break.
Stage 2: This will involve stimulation. The DBS leads will be connected to an external stimulator and a "filter DBS" device to record LFP during DBS. Four DBS conditions will be studied in random order:
- high frequency (185 Hz), 2) the individualized γ frequency that show maximum peak at rest (γ rest, determined from stage 1), 3) the individualized γ frequency that show maximum increase with voluntary movements (γ movement, determined from stage 1), and 4) no stimulation. The contact will be selected based on location within the STN from postoperative MRI using methods published by our group and maximum changes in the θ and β bands with voluntary movements (Stage 1). The selected DBS contact will be the cathode (-ve) and anode (+ve) will be a surface electrode placed on the chest wall (similar to contact -ve, case +ve commonly used in therapeutic DBS). Pulse width will be set at100 μs and the current will be the highest (maximum 5 mA) without inducing adverse effect. LFP will be recorded from the electrode contacts adjacent to the one used for DBS using a bipolar montage to allow for maximum cancellation of stimulus artifacts. For example, if contact 2 is used for DBS, LFP will be recorded from contacts 1 and 3. For each condition, 15 min of DBS while resting will be followed by mUPDRS assessment while DBS is maintained. Patients will be video recorded to allow subsequent video scoring of mUPDRS and the Rush dyskinesia rating scale by blinded raters. DBS for the right and left STN will be studied in random order, with one side in the morning and one side in the afternoon. Investigators have performed more complex stimulation protocols in PD patients with STN DBS.
The second day of study will occur the next day. The procedure will be the same as Day 1 except that the medication status (on or off medication) will alternate with Day 1 in random order.
Visit 2 (TWH-V2) The purpose of this visit is to obtain early LFP recording from the Activa PC+S device before DBS programming begins. This visit will be conducted within 4 weeks of internalization of the DBS leads and insertion of the pulse generator (Activa PC+S), but before the pulse generator is turned on for programming. The visit will be conducted over two days, one day in the off medication state (overnight withdrawal) and one day in the on medication state in random order as in Visit 1. The procedure is identical for Visit 1 with recording of LFP at rest and during a self-paced wrist extension task, followed by testing of 4 different stimulation conditions. However, LFP will be recorded from the Activa PC+S device using the real-time uplink mode to provide continuous recording rather than from externalized leads. Since the device can only record LFP from one pair of contacts from each electrode (right and left) at a time, for recordings in the resting state to examine the difference between on and off medications, investigators will use the "montage sweep" mode that will record alternately from all six possible combinations of bipolar contacts (0-1, 1-2, 2-3, 0-2, 0-3, 1-3) for each electrode. For the wrist extension movements, we will record from the bipolar contact pair that produced the greatest change in γ oscillations with dopaminergic medications and voluntary movements based on the results of Visit 1. In addition, we will record from the adjacent contact pair. For example, if contact 1-2 was found to produce the maximum γ peak, contacts 1-2 as well as contacts 0-1 and 2-3 will be studied. Each pair of electrode contacts will be studied in separate runs. Following the LFP recording (stage 1), the individual γ frequency peaks will be established. Stage 2 will study the effects of DBS at high frequency, γ rest, γ movement and no stimulation assessed in random order with recording of STN LFP during stimulation as in Visit 1. The same contact used for DBS in Visit 1 will be used with monopolar montage (contact -ve, case +ve). LFP with be recorded from the adjacent contacts with bipolar montage as described in Visit 1 but the implanted Activa PC+S device will be used for LFP recording
Visits 3- 6 (TWH-V3, V4, V5 and V6) After Visit 2, DBS programming will be performed as per usual clinical practice and takes about 2-4 weeks to complete. Patients will then be studied at 2, 6, 12, and 18 months after surgery. The assessment procedure will be identical to that for Visit 2 except that the "high" frequency stimulation setting will be the setting normally used by the patient for clinical benefit (130-185 Hz) instead of 185 Hz.
Visits at London Mobility Laboratory (Western University) Visit 1 will occur before surgery to obtain baseline gait and kinematic measurements data in the on and off medication states. For visits 2, 3 and 7, the TWH visits will occur 1-5 days before the London Mobility Laboratory visits. The γ frequency stimulation to be used in the London Mobility Laboratory visits will be the "γ movement" frequency determined from the corresponding TWH visit.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| PC+S group | – | Device: PC+S groupPC+S group gets Medtronic, Activa PC+S DBS device, |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Parkinson's disease patients scheduled to undergo STN DBS surgery
Key inclusion criteria (4 listed)
- PD Patients scheduled to undergo bilateral STN DBS surgery.
- No previous brain surgery or other neurological disorders
- No unstable medical conditions
- Able to provide informed consent and comply with study protocol
Key exclusion criteria (1 listed)
- 1. previous brain surgery or other neurological disorders unstable medical conditions
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PC+S groupPC+S group: participants in the study will also receive a specific stimulation device (Activa PC+S, Medtronic) that is capable of recording the local field potentials (LFP). Approximately 10 participants are expected to take part in this study at UHN. | Device | PC+S group |
Primary outcome
Clinical measure of Parkinsonism: Unified Parkinson's disease rating scale
Time frame: Through study completion, an average of 1.5 year
Clinical scales of Parkinson's disease will be measured using Unified Parkinson's disease rating scale at different time points (visits) of the study
2 secondary outcomes
Kinetic measures of walking
Time frame: Through study completion, an average of 1.5 year
Electrophysiologic measures of brain activity
Time frame: Through study completion, an average of 1.5 year
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Apr 2021.
- Individual participant dataSharing planned: No
Related trials for Parkinson's Disease
Enrolling by invitationObservational study
Early Molecular Biomarkers for Differentiating Parkinsonian Syndromes
PARKINSON DISEASE (Disorder), Atypical Parkinsonism
Active, not recruitingPhase 1/2
Clinical Safety and Efficacy of Umbilical Cord Mesenchymal Stromal Cells-derived Exosomes in Patients With Parkinson's Disease
Parkinson Disease (PD)
Active, not recruitingObservational study
Adaptive DBS to Offset STN Dysregulation During Exercise in PD
Parkinson Disease
Not yet recruiting
Compulsive Eating and Brain's Reward System in Different Pathologies
PARKINSON DISEASE (Disorder), Bipolar 1 Disorder
Not yet recruiting
Evaluating the Effect of the Zeen Mobility Device on Clinical Practicality, Safety, and Impact (Via Assessments of Walking, Standing Tolerance, Balance, Endurance, Effort, and Participation in Daily Tasks) in an Outpatient Rehabilitation Setting for Individuals With Mobility Impairments.
Stroke, Parkinson's Disease (PD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Robert Chen, FRCPC principal investigator
University Health Network, Toronto
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Parkinson's Disease, run by University Health Network, Toronto at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 27 Apr 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Clinical measure of Parkinsonism: Unified Parkinson's disease rating scale (time frame: Through study completion, an average of 1.5 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Apr 2021.